Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05989035 · ClinicalTrials.gov registry record · NA
Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants
A NA study of Aging, sponsored by AdventHealth Translational Research Institute.
- Active
- Registry status
- NA
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT05989035: Active NA study of Aging, sponsored by AdventHealth Translational Research Institute.
NCT05989035 is a NA study of Aging that is active but no longer recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 31 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05989035, a NA study of Aging, is active but no longer recruiting, sponsored by AdventHealth Translational Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to collect Adipose tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that Adipose tissue in the laboratory.
Primary Outcome
CXCL14 concentration (pg/ml/mg) in conditioned media
Conditions Studied
Interventions
- PROCEDURE Abdominal subcutaneous adipose tissue biopsy
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT05989035 still lists
NCT05989035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 1 intervention - of which Abdominal subcutaneous adipose tissue biopsy is the first listed.
NCT05989035 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05989035 about?
NCT05989035 is a clinical study titled "Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants". This study is being done to collect Adipose tissue from young and older individuals and gather data on the effect of methionine aminopeptidase protein (MetAP2) inhibition on that Adipose tissue in the laboratory.
What is the current status of trial NCT05989035?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 31 participants. The study started on 2020-08-31. Estimated completion is 2025-12.
What conditions does trial NCT05989035 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT05989035?
The interventions under investigation include: Abdominal subcutaneous adipose tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05989035?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05989035 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05989035's enrollment target sits among peer trials
31 192nd of 262 higher than 71 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Using Nicotine to Reverse Age-related Auditory Processing Deficits
RECRUITING · NA
-
Heterogeneity of Vascular Adaptations to Exercise With Aging in Women and Men
RECRUITING · NA
-
Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging
RECRUITING · NA
-
Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults
RECRUITING · NA
-
The GLUCID Study: Effect of Alcohol Reduction and Probiotic Interventions on Cognition and Brain Glucose Metabolism in Normal Aging Adults Who Are High-Risk Alcohol Drinkers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI